🔗 Share this article

As America continues making sweeping adjustments to its vaccination schedules, a particular individual appears unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccinations throughout the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her recent position at the Food and Drug Administration.

Planned Changes to Pediatric Vaccine Program

Health officials were set to unveil radical changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US at odds with a large portion of the international standard with insufficient data for public health gain. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Dr. Høeg is listed to speak at the meeting. She was just designated acting director of the FDA’s CDER, the fifth individual to head the division this year.

A Shift at the FDA

This interim role might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for ending some childhood shot schedules in the US so as to align more like the Danish model, a society with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

So far comments, she has continued to focus on immunizations – typically the domain of Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

Høeg has no obvious track record in medication creation, regulation or administrative roles, which has been customary for past directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for running the CDER, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She is not an expert in industry regulation.”

Previous directors of the center would “understand regulatory frameworks and the science of drug development”, noted Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed the center have had.”

This division has an vast portfolio at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the generic program approves numerous generic medications. There’s a biosimilars program, non-prescription drug unit and more, and each of these need to be looked after,” she said. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial leadership aspect to the role, which manages over 5,000 personnel. “It’s a huge leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this appointment indicates more teamwork among agency officials on immunizations, a spokesperson stated that the “inquiries are based on flawed assumptions”.

“This background aligns with the duties of her position,” the official explained, noting the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a disputed rapid therapy clearance system that apparently troubled her preceding directors. “How are these therapies being chosen for this fast-track system? Who takes the calls?” Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, except for immunizations.”

Public Track Record on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, past, some experts have noted. She authored a research paper using non-validated volunteer-provided data to assess the rate of myocarditis after COVID-19 immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new federal leadership encompassed changing rules for new vaccines and halting “optional” immunizations, she stated after the election on a audio program. At the FDA, Høeg has according to sources proposed excluding adolescent males from receiving Covid vaccines.

“She is an complete dogmatist who commences with her beliefs and tailors the evidence to accommodate the data in a very disingenuous, fraudulent fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|